Cargando…
Melatonin enhances arsenic trioxide-induced cytotoxicity by modulating autophagy in an acute promyelocytic leukemia cell line
BACKGROUND: Arsenic trioxide (ATO)-containing therapeutic strategies are widely used in the treatment of acute promyelocytic leukemia (APL). Growing evidence has shown that melatonin enhances the radio- or chemo-sensitivity of numerous cancer cells. However, whether melatonin is capable of enhancing...
Autores principales: | Wei, Xia, Pu, Xin, Yang, Sainan, Meng, Xiaoqin, Chen, Xue, Zhang, Zhihua, Sheng, Xaomin, Xiang, Dan, Zhang, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797307/ https://www.ncbi.nlm.nih.gov/pubmed/35116957 http://dx.doi.org/10.21037/tcr.2019.09.26 |
Ejemplares similares
-
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017) -
A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014) -
Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line
por: Baek, Jin Ho, et al.
Publicado: (2012) -
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
por: Li, Tao, et al.
Publicado: (2018) -
Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)